PATENT CLAIM ANALYSIS

Application Number: 16105203
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["435", "194000"]

Abstract:
The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.

Claim (Index 9):
The nucleic acid of  claim 1 , wherein, following cleavage of the fusion protein at the first and second cleavage sites, the targeting moiety of the fusion protein is capable of interacting with the binding site on the target cell via an interaction between an N-terminal domain of the targeting moiety and a domain of the binding site and simultaneously via an interaction between a C-terminal domain of the targeting moiety and a domain of the binding site.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.60465
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14117286', '13774587', '12862948', '13738235', '13239573']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6612426839526516
- 35 USC 102 Novelty (BERT): 0.564115312836422
- Combined Prediction Score: 0.6515299468410286
- Mean Citation Score: 420.549464
- Max Citation Score: 466.78696
- Similarity Product: 332.10967979387766

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test